Zelira Therapeutics Limited (ZLD.AX)
AUD 0.38
(0.0%)
AUD 0.38
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -5.93 Million AUD | 19.89% |
| 2023 | -7.41 Million AUD | 44.74% |
| 2022 | -13.41 Million AUD | -38.98% |
| 2021 | -9.65 Million AUD | -23.14% |
| 2020 | -7.83 Million AUD | -85.44% |
| 2019 | -4.22 Million AUD | -50.13% |
| 2018 | -2.81 Million AUD | -9.54% |
| 2017 | -2.57 Million AUD | -193.28% |
| 2016 | -876.42 Thousand AUD | -106.79% |
| 2015 | -423.82 Thousand AUD | -43.58% |
| 2014 | -295.17 Thousand AUD | 8.35% |
| 2013 | -322.06 Thousand AUD | 48.93% |
| 2012 | -630.62 Thousand AUD | -36.18% |
| 2011 | -463.08 Thousand AUD | 58.51% |
| 2010 | -1.11 Million AUD | 39.82% |
| 2009 | -1.85 Million AUD | -280.06% |
| 2008 | -487.99 Thousand AUD | 97.74% |
| 2007 | -21.62 Million AUD | -1607.54% |
| 2006 | -1.26 Million AUD | -169.8% |
| 2005 | -469.35 Thousand AUD | 30.76% |
| 2004 | -677.83 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -2.83 Million AUD | 0.0% |
| 2024 Q2 | -3.33 Million AUD | 0.0% |
| 2024 FY | -6.17 Million AUD | 16.73% |
| 2023 Q4 | -3.91 Million AUD | 0.0% |
| 2023 FY | -7.41 Million AUD | 44.74% |
| 2023 Q2 | -3.49 Million AUD | 0.0% |
| 2022 FY | -13.41 Million AUD | -38.98% |
| 2022 Q2 | -5.28 Million AUD | 0.0% |
| 2022 Q4 | -8.12 Million AUD | 0.0% |
| 2021 Q2 | -5.05 Million AUD | 0.0% |
| 2021 FY | -9.65 Million AUD | -23.14% |
| 2021 Q4 | -4.59 Million AUD | 0.0% |
| 2020 Q4 | -4.22 Million AUD | 0.0% |
| 2020 Q2 | -3.33 Million AUD | 0.0% |
| 2020 FY | -7.83 Million AUD | -85.44% |
| 2019 Q4 | -2.32 Million AUD | 0.0% |
| 2019 FY | -4.22 Million AUD | -50.13% |
| 2019 Q2 | -1.82 Million AUD | 0.0% |
| 2018 Q4 | -1.17 Million AUD | 0.0% |
| 2018 FY | -2.81 Million AUD | -9.54% |
| 2018 Q2 | -1.19 Million AUD | 0.0% |
| 2017 FY | -2.57 Million AUD | -193.28% |
| 2017 Q4 | -1.09 Million AUD | 0.0% |
| 2017 Q2 | -1.35 Million AUD | 0.0% |
| 2016 Q4 | -319.17 Thousand AUD | -45.67% |
| 2016 Q1 | -105.95 Thousand AUD | 0.0% |
| 2016 Q2 | 158.07 Thousand AUD | 249.18% |
| 2016 Q3 | -219.1 Thousand AUD | -238.61% |
| 2016 FY | -876.42 Thousand AUD | -106.79% |
| 2015 Q3 | -105.95 Thousand AUD | 0.0% |
| 2015 Q1 | -73.79 Thousand AUD | 0.0% |
| 2015 Q4 | -105.95 Thousand AUD | 0.0% |
| 2015 Q2 | -105.95 Thousand AUD | -43.58% |
| 2015 FY | -423.82 Thousand AUD | -43.58% |
| 2014 Q1 | -80.51 Thousand AUD | 0.0% |
| 2014 Q2 | -73.79 Thousand AUD | 8.35% |
| 2014 Q3 | -73.79 Thousand AUD | 0.0% |
| 2014 Q4 | -73.79 Thousand AUD | 0.0% |
| 2014 FY | -295.17 Thousand AUD | 8.35% |
| 2013 Q3 | -80.51 Thousand AUD | 0.0% |
| 2013 Q1 | -157.65 Thousand AUD | 0.0% |
| 2013 Q2 | -80.51 Thousand AUD | 48.93% |
| 2013 FY | -322.06 Thousand AUD | 48.93% |
| 2013 Q4 | -80.51 Thousand AUD | 0.0% |
| 2012 FY | -630.62 Thousand AUD | -36.18% |
| 2012 Q3 | -157.65 Thousand AUD | 0.0% |
| 2012 Q2 | -157.65 Thousand AUD | -36.18% |
| 2012 Q1 | -115.77 Thousand AUD | 0.0% |
| 2012 Q4 | -157.65 Thousand AUD | 0.0% |
| 2011 Q4 | -115.77 Thousand AUD | 0.0% |
| 2011 Q3 | -115.77 Thousand AUD | 0.0% |
| 2011 FY | -463.08 Thousand AUD | 58.51% |
| 2011 Q2 | -115.77 Thousand AUD | 58.51% |
| 2011 Q1 | -279.01 Thousand AUD | 0.0% |
| 2010 Q4 | -279.01 Thousand AUD | 0.0% |
| 2010 Q3 | -279.01 Thousand AUD | 0.0% |
| 2010 FY | -1.11 Million AUD | 39.82% |
| 2010 Q2 | -279.01 Thousand AUD | 39.82% |
| 2010 Q1 | -463.67 Thousand AUD | 0.0% |
| 2009 Q2 | -463.67 Thousand AUD | -280.06% |
| 2009 Q1 | -121.99 Thousand AUD | 0.0% |
| 2009 Q4 | -463.67 Thousand AUD | 0.0% |
| 2009 FY | -1.85 Million AUD | -280.06% |
| 2009 Q3 | -463.67 Thousand AUD | 0.0% |
| 2008 FY | -487.99 Thousand AUD | 97.74% |
| 2008 Q4 | -121.99 Thousand AUD | 0.0% |
| 2008 Q3 | -121.99 Thousand AUD | 0.0% |
| 2008 Q1 | -5.4 Million AUD | 0.0% |
| 2008 Q2 | -121.99 Thousand AUD | 97.74% |
| 2007 FY | -21.62 Million AUD | -1607.54% |
| 2007 Q1 | -316.58 Thousand AUD | 0.0% |
| 2007 Q2 | -5.4 Million AUD | -1607.54% |
| 2007 Q3 | -5.4 Million AUD | 0.0% |
| 2007 Q4 | -5.4 Million AUD | 0.0% |
| 2006 FY | -1.26 Million AUD | -169.8% |
| 2006 Q2 | -316.58 Thousand AUD | -169.8% |
| 2006 Q3 | -316.58 Thousand AUD | 0.0% |
| 2006 Q1 | -117.33 Thousand AUD | 0.0% |
| 2006 Q4 | -316.58 Thousand AUD | 0.0% |
| 2005 Q2 | -117.33 Thousand AUD | 30.76% |
| 2005 Q1 | -169.45 Thousand AUD | 0.0% |
| 2005 Q4 | -117.33 Thousand AUD | 0.0% |
| 2005 Q3 | -117.33 Thousand AUD | 0.0% |
| 2005 FY | -469.35 Thousand AUD | 30.76% |
| 2004 Q4 | -169.45 Thousand AUD | 0.0% |
| 2004 FY | -677.83 Thousand AUD | 0.0% |
| 2004 Q3 | -169.45 Thousand AUD | 0.0% |
| 2004 Q2 | -169.45 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -12.86% |
| Acrux Limited | -9.83 Million AUD | 39.615% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -34.198% |
| Biome Australia Limited | -1.91 Million AUD | -210.376% |
| BTC Health Limited | 1.05 Million AUD | 662.712% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 51.76% |
| CSL Limited | 5.64 Billion AUD | 100.105% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 86.745% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 112.082% |
| Noxopharm Limited | -7.53 Million AUD | 21.191% |
| PharmAust Limited | -6.65 Million AUD | 10.819% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 17.884% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 17.369% |
| PYC Therapeutics Limited | -38.85 Million AUD | 84.718% |
| Race Oncology Limited | -13.38 Million AUD | 55.62% |
| Starpharma Holdings Limited | -15.15 Million AUD | 60.827% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 161.115% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 59.603% |
| Memphasys Limited | -2.7 Million AUD | -119.609% |
| Nyrada Inc. | -4.56 Million AUD | -30.215% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -306.971% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -93.904% |
| Patrys Limited | -3.53 Million AUD | -67.787% |
| Dimerix Limited | -25.05 Million AUD | 76.304% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 102.628% |
| Orthocell Limited | -11.68 Million AUD | 49.164% |
| Imugene Limited | -140.93 Million AUD | 95.786% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 32.581% |
| Immutep Limited | -44.93 Million AUD | 86.785% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 17.445% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 69.706% |
| Nanollose Limited | -1.24 Million AUD | -375.125% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -178.316% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -188.746% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -106.635% |
| Biotron Limited | -5.15 Million AUD | -15.279% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 87.422% |
| Tissue Repair Ltd | -4.87 Million AUD | -21.786% |
| AnteoTech Limited | -11.72 Million AUD | 49.361% |
| Hexima Limited | -1 Million AUD | -488.672% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 90.88% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 73.071% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -29.396% |
| Actinogen Medical Limited | -12.83 Million AUD | 53.748% |
| Immuron Limited | -5.8 Million AUD | -2.364% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -4.708% |